Senolytics and Zombie Cells: What We Really Know in Humans

“Zombie cells” is an irresistible name. It is also perfect territory for selling the happy ending before the trial is finished. The idea of clearing senescent cells has produced striking results in mice and has reached studies in people. That deserves attention. It does not turn an oncology drug, a fisetin capsule or a quercetin infusion into a proven anti-ageing treatment.

The honest answer fits in one sentence: senolytics are a promising scientific strategy, but clinical efficacy in humans remains unproven. Researchers have found signs of biological activity, completed small feasibility studies, reported negative results and exposed hard questions about whom to treat, which cell to remove and how to know whether benefit outweighs harm.

This guide focuses on treatments and human evidence. If you want the biology first, start with what cellular senescence is. If you have seen a p16 test advertised as a “zombie-cell counter”, also read why that marker is not an individual verdict.

Editorial review: August 2026. This article is educational and does not replace medical assessment. Do not use dasatinib, high-dose combinations or products sold as senolytic protocols outside an authorised indication or a supervised clinical trial. Dasatinib is an oncology medicine with important risks and interactions.

First, what is a senescent cell?

A senescent cell has entered a stable cell-cycle arrest and changed how it functions. It often resists death signals and alters what it releases into its surroundings. Some of those signals are grouped under the term SASP, or senescence-associated secretory phenotype, and include inflammatory mediators, growth factors and tissue-remodelling enzymes.

The zombie metaphor helps us picture a cell that no longer divides but still influences its neighbours. It is also slightly misleading. There is no single senescent-cell type and no identical SASP across every organ. Senescence can be temporary and useful in development, wound repair or damage containment. It can become persistent and harmful in other settings. The scientific consensus by Gorgoulis and colleagues emphasises this diversity and the lack of a universal marker.

“Killing zombie cells” is therefore not as simple as emptying a bin. A therapy must recognise the problematic population, reach the right tissue, preserve useful functions and demonstrate an outcome that matters to the person. A mechanism is the beginning of the story, not the ending.

What a senolytic does, and what it does not do

A senolytic attempts to exploit survival pathways in a senescent cell and trigger its death. A senomorphic instead seeks to modulate harmful features, such as parts of the SASP, without removing the cell. These labels are used widely in laboratory research, but the same molecule can behave differently depending on cell type, dose and model.

To read a headline without being carried away by it, separate three levels of evidence:

1. An effect in cells or animals: this establishes biological possibility, not that the intervention is effective or safe in people.
2. Human target engagement: a marker changes, the compound reaches a tissue or an associated signal falls. This matters, but still does not prove benefit.
3. A clinical outcome: function, symptoms, disease or survival improve against an appropriate comparison, with acceptable harm.

Experiments that removed p16-positive cells in ageing mice helped establish the field. In 2016, a Nature study found improvements in several tissues and longer healthy survival in that model. In 2018, Xu and colleagues observed better physical function and survival after a senolytic combination in old mice. These are important preclinical findings. They are not instructions for a person.

The best-known candidates, in context

Candidate	What is being studied	Human status	Main limit
Dasatinib + quercetin (D+Q)	A combination acting on different cell-survival pathways	Small pilots and one randomised trial in postmenopausal women	Clinical efficacy unproven; dasatinib can cause toxicity and interactions
Fisetin	A flavonoid with senotherapeutic activity in preclinical models	Ongoing or early trials; no proof of rejuvenation	Uncertain bioavailability, dose, product and clinical outcomes
Navitoclax	Inhibition of BCL-2 family proteins	Investigated mainly in oncology and preclinical senescence models	Thrombocytopenia and insufficient selectivity for preventive use
UBX0101	An intra-articular injection studied in knee osteoarthritis	A completed phase 2 trial with 183 participants	No clear benefit on the primary pain endpoint
Next-generation targeted therapies	Prodrugs, antibodies, immunotherapy and tissue-specific delivery	Mostly preclinical or in early development	Specific targets, reproducibility and long-term safety

Dasatinib is not a supplement. It is a tyrosine kinase inhibitor used in certain cancers and can cause cytopenias, bleeding, fluid retention and other complications, as well as drug interactions. Intermittent use does not erase those risks. Quercetin in food is also not equivalent to the gram-level amounts used in some experiments.

Fisetin has attracted interest because it occurs in foods and showed effects in laboratory models. But a “natural” molecule may require difficult-to-reach concentrations, have poor bioavailability or behave differently in people. A review of nutritional senotherapeutics summarises these problems of dose, absorption and limited human evidence.

What studies in people have actually found

Idiopathic pulmonary fibrosis: feasibility, not confirmation

The pilot published in 2019 enrolled 14 people with idiopathic pulmonary fibrosis. They received dasatinib 100 mg and quercetin 1,250 mg for three days a week over three weeks. It was open-label, had no placebo and was primarily designed to see whether the schedule was feasible. Some physical tests changed in exploratory analyses, but the study did not establish disease improvement. It also recorded one serious adverse event. Read the study by Justice and colleagues.

That distinction changes the conclusion. “People completed a pilot” does not mean “the treatment works”. With 14 participants and no control group, practice, natural variation and expectations can influence functional tests.

Diabetic kidney disease: a biological signal in nine people

Another study gave D+Q for three days to nine people with diabetic kidney disease and collected samples 11 days later. Several senescence-associated and SASP markers fell in adipose tissue and blood. This is a target-engagement signal, not evidence that kidney function improves, dialysis is prevented or life is extended. The design and results appear in the report by Hickson and colleagues.

Alzheimer's disease: five participants and a penetration question

A 2023 phase 1 study included five people with mild symptomatic Alzheimer's disease. Dasatinib was detected in cerebrospinal fluid in four; quercetin was not detected. There were no significant cognitive or neuroimaging changes, and some biomarkers moved in directions that were difficult to interpret. The purpose was feasibility and penetration, not efficacy. It should not be turned into “positive results against Alzheimer's”. Read the SToMP-AD study.

Bone health: the randomised trial that cooled enthusiasm

A phase 2 randomised controlled trial in 60 postmenopausal women was published in 2024. Compared with control, D+Q did not reduce the chosen bone-resorption marker at 20 weeks, its primary endpoint. A transient bone-formation signal appeared, and an exploratory analysis suggested that a subgroup with high p16 might respond differently. That generates a hypothesis, not a clinical indication. The full Nature Medicine trial reported no serious adverse events.

A subsequent analysis showed that p16 variants and SASP panels can classify participants differently. Rather than providing a clinic-ready test, the biomarker-selection study illustrates how much still needs standardising.

UBX0101: failure teaches us too

UBX0101 was developed as a local injection for knee osteoarthritis. Its registered phase 2 trial assigned 183 participants to three doses or placebo and assessed pain at 12 weeks. The programme did not show a clear benefit on the primary endpoint. This does not invalidate the whole field. It does show that an attractive rationale and preclinical results do not guarantee that one candidate will relieve a human disease.

Why measuring a “senescent burden” is not routine medicine

No single test detects every senescent cell. p16 and p21 also appear in other processes. SA-β-gal activity is not exclusive. IL-6, IL-8 and other SASP components change with infection, exercise, visceral fat and many diseases. A blood sample also does not necessarily represent what is happening in lung, bone, brain or cartilage.

Researchers combine markers, morphology, function and tissue context. In a clinic, turning one result into a whole-body percentage or an automatic treatment order adds precision that the science does not have. If inflammation is your main concern, our guide to inflammaging and biomarkers separates a scientific concept from disease and blood-test interpretation.

Recent reviews still identify heterogeneity, marker specificity and long-term safety as central barriers. Reproducibility matters too: a 2026 cross-laboratory preclinical study failed to reproduce several reported senolytic effects for other strategies. Updating a conclusion when new data arrive does not weaken science. It is science working.

Exercise, food, sleep and fasting: benefits without costumes

Exercise improves cardiorespiratory fitness, strength, glucose regulation, blood pressure, mood and independence. It may alter signals linked to inflammation or senescence, but it has not been shown to act as a human senolytic that selectively destroys zombie cells. It does not need embellishment: those benefits are already substantial.

A good-quality diet also supports cardiometabolic health. Quercetin, fisetin, curcumin or EGCG in food do not turn a salad into senolytic chemotherapy. For a practical foundation, use our anti-inflammatory eating guide without magic lists.

Fasting has the same translation problem. Autophagy and senescence interact in experimental models, but nobody can state the exact hour when a fast starts clearing senescent cells in a person. An earlier dinner or limited eating window may suit some lives; it is not a senolytic protocol. Our guide to intermittent fasting and autophagy explains the distinction.

How to assess an offer without losing your curiosity

An experimental treatment is not destined to fail. It needs the safeguards of a serious experiment. Before accepting a “senolytic protocol”, ask:

• Which specific condition is being treated, and is that indication authorised?
• Is this clinical care or a registered trial? What is the registration number?
• Is the primary outcome a marker or something I will notice in health and function?
• What evidence exists in people like me, and how many took part?
• Which adverse effects, interactions and exclusion criteria are monitored?
• Who prescribes, who manages a complication and what triggers stopping?

Be cautious if the answer begins with a package of intravenous NAD+, ozone, plasmapheresis or hyperbaric oxygen presented as a senescent-cell cleanse. None is an established senolytic treatment. Our guide to longevity clinics and warning signs offers a broader framework for evaluating tests, costs and follow-up.

An honest consultation can review medication, risk, symptoms, prevention and whether a suitable trial exists. It cannot reliably measure your whole-body senescent-cell burden or promise that an experimental cocktail will rejuvenate your tissues. If you want to organise those questions, you can start an assessment with the Progevita team.

Frequently asked questions

What exactly is a senolytic?

It is a substance designed to trigger the death of certain senescent cells by exploiting vulnerabilities that help them survive. The word describes an experimental mechanism, not a guarantee of rejuvenation. Effects depend on cell type, tissue, disease, dose and timing.

Are all zombie cells harmful?

No. Senescence can help stop damaged cells, repair wounds and coordinate normal processes. Problems may arise when some cells persist, accumulate in particular tissues or disrupt their surroundings. A therapeutic goal should not be to erase all senescence.

Is any senolytic approved to treat ageing?

No senolytic is approved specifically to delay ageing in healthy people. Dasatinib is authorised for certain cancers, not as an anti-ageing treatment. Other candidates remain in clinical or preclinical research.

Has dasatinib plus quercetin been proven to rejuvenate people?

No. Small studies have shown feasibility or biomarker changes, but they have not demonstrated rejuvenation, longer life or lasting clinical benefit. A 2024 randomised trial also missed its primary bone-resorption endpoint.

Can I take fisetin or quercetin on my own?

Being sold as a supplement does not prove that a product acts as a senolytic in people or that high doses are harmless. Quality can vary and interactions can occur. Do not copy laboratory or trial doses without reviewing the indication, product, health history and regular medication.

Can my senescent-cell burden be measured?

There is currently no single, validated routine test that reports a whole-body senescent-cell burden and guides treatment. p16, p21, SA-β-gal and SASP components provide research clues, but none identifies every senescent cell on its own.

Do exercise or fasting work as natural senolytics?

They have not been shown to selectively clear senescent cells in humans as a senolytic drug is intended to do. Exercise, diet and sleep do improve health outcomes and may influence pathways linked to inflammation, metabolism or senescence. Those benefits do not need the label senolysis.

What can I do now if this field interests me?

Prioritise prevention with proven clinical benefit, review risk factors and do not buy a protocol solely because it changes biomarkers. If considering a trial, check its registration, endpoint, oversight, entry criteria and adverse-event monitoring. For a commercial offer, ask the provider to separate human evidence, hypothesis and marketing.

Sources

1. Gorgoulis V et al. Cellular Senescence: Defining a Path Forward. Cell. 2019. PMID: 31675495.
2. Baker DJ et al. Naturally occurring p16(Ink4a)-positive cells shorten healthy lifespan. Nature. 2016. PMID: 26840489.
3. Xu M et al. Senolytics improve physical function and increase lifespan in old age. Nature Medicine. 2018. PMID: 29988130.
4. Justice JN et al. Senolytics in idiopathic pulmonary fibrosis: first-in-human open-label pilot. EBioMedicine. 2019. PMID: 30616998.
5. Hickson LJ et al. Senolytics decrease senescent cells in humans: preliminary report. EBioMedicine. 2019. PMID: 31542391.
6. Gonzales MM et al. Senolytic therapy in mild Alzheimer's disease: a phase 1 feasibility trial. Nature Medicine. 2023. PMID: 37679434.
7. Farr JN et al. Intermittent senolytic therapy in postmenopausal women: a phase 2 randomised trial. Nature Medicine. 2024. PMID: 38956196.
8. Doolittle ML et al. Biomarkers associated with response to intermittent D+Q in postmenopausal women. 2025. PMID: 39823170.
9. ClinicalTrials.gov. Phase 2 study of UBX0101 in knee osteoarthritis. NCT04129944.
10. Brennan A et al. Cross-laboratory evaluation of candidate senolytic strategies. 2026. PMID: 41933117.
11. Review of nutritional senotherapeutics and barriers to clinical translation. 2026. PMID: 42609608.

Method: narrative review of foundational preclinical studies, published human trials, trial registration and recent reviews. Effects in animals, target engagement and clinical benefit are treated as separate levels of evidence. Regulatory information and trial status were reviewed in August 2026.